News Releases

Rahway, N.J. – Sept. 13, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced new data demonstrating the safety and efficacy of NUMELVI® (atinvicitinib) Tablets for Dogs and MOMETAMAX ULTRA® (gentamicin, posaconazole, and mometasone furoate otic suspension) for dogs. These data were presented at the 35th […]

Read more

NUMELVI, a highly-selective, second-generation JAK inhibitor for dogs, delivers at least 10-fold greater selectivity for JAK1 compared with JAK2, JAK3, and tyrosine kinase (TYK)–2, and is suitable for dogs as young as 6 months. RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today […]

Read more

NUMELVI from MSD Animal Health is the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., July 24, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., […]

Read more

Rahway, NJ., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines. If the European Commission (EC) adopts the recommendation, the […]

Read more

If approved by the European Commission, the vaccine will become an available tool for governments to consider as part of a holistic strategy to combat the spread of highly pathogenic avian influenza (HPAI) which may include additional vaccinations plus enhanced biosecurity and surveillance Potentially the first centrally registered vaccine in the European Union against the […]

Read more